BioInvent Presents Positive Data for BI-505 at International Myeloma
Congress
LUND, Sweden--(
BUSINESS WIRE)--BioInvent International AB (OMXS:BINV) announce that the previously
communicated positive results from a phase I trial of BI-505 is
presented today at The International Myeloma Workshop in Kyoto, Japan.
At the same meeting, preclinical data is also presented which
demonstrate significantly enhanced efficacy when approved myeloma drugs
are combined with BI-505. BI-505 is a human antibody directed against
ICAM-1 and is developed for the treatment of multiple myeloma.
The results from the phase I study of BI-505 in patients with advanced
multiple myeloma are presented by Associate Professor Markus Hansson at
Lund University. The preliminary analysis shows that BI-505 has an
advantageous safety profile. In cohorts where extended treatment was
available, 24 percent of the patients had stable disease for at least
two months, indicating effect of BI-505.
At the same meeting, new preclinical data is also presented showing
significantly enhanced anti-myeloma activity when the approved drugs
Velcade
® or Revlimid® is combined with BI-505 compared to
single agent treatment. Combined treatment was evaluated in two
different experimental models and the drugs were given in a similar way
as to patients with myeloma. In one of the models enhanced survival was
observed following combination therapy with BI-505, compared to single
agent treatment with the approved drugs. In the second model, complete
remission was observed in the majority of animals when combining BI-505
with Revlimid
® or Velcade
®.
Cristina Glad, CEO for BioInvent, commented: “We believe BI-505 has the
potential to address a major unmet medical need in a broad population of
patients with multiple myeloma. Based on the results from the phase I
trial which are now presented at the international myeloma meeting, we
have decided to continue our studies on BI-505 with a new smaller trial
in patients with asymptomatic multiple myeloma (called “smoldering
multiple myeloma”). The interesting preclinical studies showing enhanced
anti-tumor effect when combining BI-505 with approved drugs, support to
move forward with a clinical trial in which BI-505 is combined with
another drug, representing a logic continuation of the clinical
development process for our hitherto most advanced project.”